OPK Opko Health Inc.

6.70
-0.10  -1%
Previous Close 6.80
Open 6.79
Price To book 1.78
Market Cap 3748013105
Shares 559,404,941
Volume 4,244,196
Short Ratio 12.04
Av. Daily Volume 4,858,922

SEC filingsSee all SEC filings

  1. 8-K - Current report 171133786
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171094042
  3. 8-K - Current report 171072975
  4. SD - 171060827
  5. 8-K - Current report 171037689

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2b trial to be initiated early 2018.
OPK88003
Obesity and diabetes
Phase 2a trial to be initiated later in 2017.
OPK88002
Pruritus in Stage 5 CKD patients undergoing dialysis
Phase 2 trial to be initiated 4Q 2017.
OPK88001
Dravet Syndrome
Phase 2b trial to be initiated 2H 2017.
TT701 (selective androgen receptor modulator)
Benign Prostatic Hyperplasia (BPH)
Phase 2b trial to be initiated 4Q 2017.
OPK88004
Benign Prostatic Hyperplasia (BPH)
Phase 2 trial to be initiated 2H 2017.
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) - Stage 5
Phase 3 data released December 30, 2016 - primary endpoint not met.
hGH-CTP
Adults - growth hormone deficiency
Phase 3 initiation announced December 30, 2016.
hGH-CTP
Children - growth hormone deficiency
Announced June 21 2016 FDA Approval
RAYALDEE
Secondary hyperparathyroidism (SHPT) in chronic kidney disease (CKD) and vitamin D insufficiency - Stage 3 and 4
Phase 2 ongoing as of September 2017.
Factor VIIa-CTP
Hemophilia
Phase 3 to be initiated 1H 2018.
Fermagate Tablets
hyperphosphatemia in CKD patients on chronic hemodialysis
Approved September 2, 2015.
Rolapitant
Prevention of chemotherapy induced nausea and vomiting, or CINV

Latest News

  1. Where Will Opko Health Inc. Be in 5 Years?
  2. ETFs with exposure to OPKO Health, Inc. : October 16, 2017
  3. OPKO Health (OPK) Signs New Agreement with Japan Tobacco
  4. Opko Health inks deal to bring new drug to Japan, generate more than $100M in revenue
  5. OPKO Health Enters into Exclusive Agreement with Japan Tobacco to Develop and Commercialize RAYALDEE® in Japan
  6. These are the highest-paid tech executives in South Florida
  7. Today's Research Reports on Trending Tickers: Opko Health and Pulmatrix
  8. OPKO Health, Inc. is trading above its 50 day moving average : OPK-US : September 27, 2017
  9. ETFs with exposure to OPKO Health, Inc. : September 22, 2017
  10. OPKO Health, Inc. :OPK-US: Earnings Analysis: Q2, 2017 By the Numbers : September 21, 2017
  11. Today's Research Reports on Trending Tickers: Amicus Therapeutics and Opko Health
  12. OPKO’s BioReference Laboratories and The Garage Announce National Strategic Affiliation to Enhance Value-Based Care
  13. Why Opko Health, Avis Budget Group, and Adomani Slumped Today
  14. Here's Why the Best Is Yet to Come for Opko Health Inc.
  15. Biotech Stocks That Could Have Investors Looking At A Billion-Dollar Opportunity
  16. OPKO Health, Inc. breached its 50 day moving average in a Bullish Manner : OPK-US : September 13, 2017
  17. Is the Options Market Predicting a Spike in Opko Health (OPK) Stock?
  18. OPKO’s GeneDx to Showcase Leadership in Genetic Testing at the National Society of Genetic Counselors and the American Society of Human Genetics Annual Meetings

SEC Filings

  1. 8-K - Current report 171133786
  2. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership 171094042
  3. 8-K - Current report 171072975
  4. SD - 171060827
  5. 8-K - Current report 171037689
  6. SC 13D/A [Amend] - General statement of acquisition of beneficial ownership
  7. 8-K - Current report 171014995
  8. 10-Q - Quarterly report [Sections 13 or 15(d)] 171014934
  9. SC 13D - General statement of acquisition of beneficial ownership
  10. 8-K - Current report 17913813